Perampanel during pregnancy: Description of four cases

A.M. Alicino, G. Falcicchio, G. Boero, G. Santarcangelo, T. Francavilla, M. Trojano, A. La Neve

A Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy
b Complex Structure of Neurology, SS Annunziata Hospital, Taranto, Italy
c Territorial Neurology Service, Policoro, ASM Matera, Italy

Article Info

Article history:
Received 30 July 2021
Revised 15 September 2021
Accepted 26 September 2021
Available online 8 October 2021

Keywords:
Epilepsy
Perampanel
Pregnancy
Anti-seizure medications (ASMs)
Neonatal major malformations

Abstract

Perampanel (PER) is approved in Italy as an adjunctive treatment for focal-onset seizures (FOS) and generalized tonic-clonic seizures (GTCs), and it could be an alternative to valproate in young women diagnosed with idiopathic generalized epilepsy. Nevertheless, clinical data about the outcome of pregnancies in women exposed to PER are lacking. Here, we report retrospectively collected data from four women suffering from FOS who were exposed to PER during pregnancy. Three pregnancies were carried out with PER as add-on therapy during the entire gestation (8 mg/day in two patients and 6 mg/day in one), without seizure frequency variations. The fourth patient started PER 2 mg/day as monotherapy during the 13th week of pregnancy due to seizure relapse and continued it until delivery with complete seizure control. All pregnancies showed good outcomes, and their newborns did not possess major congenital malformations. Apgar scores and auxological parameters at birth were normal. Fetal pathology in follow-up during pregnancies was absent in all cases. In our patients PER was well tolerated and appeared safe for the fetuses and did not result in major malformations or adverse events at birth. Nevertheless, this is a report involving a small number of patients and it does not suggest the general use of PER is safe during pregnancy.

1. Introduction

The use of newer anti-seizure medications (ASMs) during pregnancies is growing worldwide [1] due to their increasing utilization in epilepsy and other diseases, such as bipolar disorders and neuropathic pain [2].

Therefore, there is a need to assess their safety in utero to evaluate the balance among their therapeutic effects and the potential risk of adverse events in the exposed foetus.

Perampanel (PER) is a second-generation ASM licensed in Italy in 2012 as adjunctive therapy for focal-onset seizures (FOS) and generalized tonic-clonic seizures (GTCs). Interestingly, due to numerous studies on its efficacy in generalized epilepsies [3], PER represents a potential alternative to valproate, where the high risk for a teratogenic effect has been demonstrated [4]. Preclinical studies in pregnant rats and rabbits indicate that PER may cause post-implantation loss, diverticulum of the intestine, and delays in physical development [5].

There have not been any adequate clinical studies to assess the outcomes of pregnancies in women exposed to PER during gestation; only single reports or data about few cases of pregnancies are available, none of which are from the European Registry of Antiepileptic Drugs and Pregnancy (EURAP) [6].

While waiting for future data from large systematic collections of pregnancies with PER, single clinical experiences can be very useful to guide therapy.

We report data from four pregnancies of women affected by epilepsy who were exposed to PER.

2. Material and methods

We retrospectively reviewed clinical records and identified four pregnancy exposures to PER. Three patients were followed by the Epilepsy Centre of the University of Bari, and one patient was followed by the Neurological Outpatient Ambulatory of Policoro Hospital. We evaluated seizure frequency before and during gestation, maternal and fetal side effects, screening tests during pregnancy, pregnancy course, delivery, birth outcomes, and auxological features of the newborns. None of the pregnancies were planned despite previous counselling.

https://doi.org/10.1016/j.ebr.2021.100490
2589-9864/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
4. Results

**Patient 1**: She was a 43-year-old woman at the time of pregnancy affected by drug-resistant focal epilepsy due to left temporal focal cortical dysplasia. Seizures were characterized by an epigastric aura followed by impairment of awareness and automatisms. At the beginning of pregnancy, she was taking PER 8 mg/day along with zonisamide 500 mg/day. The seizure frequency was one per month, and remained stable during pregnancy. No therapeutic changes were made until delivery. Morphological ultrasounds were performed in each trimester with normal findings, and cardiac doppler ultrasound was normal in the second trimester. Pregnancy was full-term and resulted, after cesarean section, in a normal live birth without evidence of major malformations. The complete time of fetal exposure to PER was 275 days. The birth weight was 2660 g, length 47 cm, and Apgar score 9–10.

**Patient 2**: She was a 28-year-old woman at the time of pregnancy affected by drug-resistant focal epilepsy of unknown etiology. At the beginning of pregnancy, she was on treatment with PER 8 mg/day, topiramate 800 mg/day, and carbamazepine 1800 mg/day; seizures, with right sensory onset followed by impairment of awareness and automatisms, had a monthly frequency and were stable during pregnancy. Therapy remained unchanged until delivery.

There were no pathological findings in morphological ultrasounds performed every quarter of pregnancy, and cardiac doppler ultrasound was performed in the second trimester. In the 18th week, a risk of miscarriage occurred, but it spontaneously resolved. A full-term pregnancy resulted in a normal live birth after cesarean section, and no major malformations were detected. The fetus was exposed to PER for 270 days. The birth weight was 2690 g, length 47 cm, and Apgar score 9–10.

**Patient 3**: She was a 21-year-old female patient affected by drug-resistant focal epilepsy of unknown etiology. At the beginning of pregnancy, she was on treatment with PER 8 mg/day, topiramate 800 mg/day, and carbamazepine 1800 mg/day; seizures, with right sensory onset followed by impairment of awareness and automatisms, had a monthly frequency and were stable during pregnancy. Therapy remained unchanged until delivery.

There were no pathological findings in morphological ultrasounds performed every quarter of pregnancy, and cardiac doppler ultrasound was performed in the second trimester. In the 18th week, a risk of miscarriage occurred, but it spontaneously resolved. A full-term pregnancy resulted in a normal live birth after cesarean section, and no major malformations were detected. The fetus was exposed to PER for 270 days. The birth weight was 2690 g, length 47 cm, and Apgar score 9–10.

**Patient 4**: She was a 33-year-old pregnant patient affected by drug-resistant focal epilepsy of unknown etiology. At the beginning of pregnancy, she was taking PER 6 mg/day along with zonisamide 500 mg/day and oxcarbazepine 1200 mg/day. Focal onset seizures with impairment of awareness were weekly and remained stable during pregnancy. Therapy was not modified during gestation. No alterations were detected via the morphological ultrasounds performed during pregnancy, and the cardiac doppler ultrasound was normal. A live birth occurred after a full-term pregnancy with caesarean section; there was no evidence of major malformations. In total, fetal exposure to PER was 272 days. The birth weight was 2690 g, length 47 cm, and Apgar score 9–10.

The main clinical features of the patients, pregnancies, and newborns are summarized in Table 1.

5. Discussion

All four pregnancies demonstrated good outcomes, and none of the newborns had major malformations. The Apgar scores were normal, as were auxological parameters. Fetal follow-up during pregnancy was not pathological in any case.

In three cases, exposure to PER lasted the entire pregnancy, at a dose of 8 mg/day in two cases and 6 mg/day in the third case. PER was associated with one concomitant ASM in patient 1 and with two concomitant ASMs in patients 2 and 4. Patient 3 started pregnancy without assuming any ASM, but she started PER 2 mg/day after seizure relapse in the 13th week of gestation, and continued for the entire pregnancy; this patient should be considered apart from the others ones in relation to the beginning of the therapy after the first trimester of pregnancy, when the potential teratogenic period was exceeded.

There was only one threat of miscarriage, which occurred in patient 2 at the 18th week and she recovered spontaneously. In the absence of seizure-related complications, cesarean section was performed in three pregnancies due to gynecological decisions.

No information about neuropsychological consequences can be provided due to the brief follow-up after delivery.

All our patients were affected by focal epilepsies, and seizure frequencies remained stable during pregnancy; in patient 3, no further seizures were registered after PER monotherapy was started again. Even though PER plasma concentrations were not available in our sample, the unmodified seizure frequencies during pregnancies suggest that PER plasma levels may have remained in the therapeutic range.

Considering older ASMs, clinical data in humans have always confirmed the results of preclinical studies conducted in animal models. In preclinical studies in pregnant rats and rabbits, PER doses of 1 mg/kg/day corresponded to 8 mg/day in humans [7], and no teratogenic effects emerged with doses of 1 mg, 10 mg, or 30 mg/day (Table 2). To confirm preclinical data about PER, larger studies and larger registries of pregnant women exposed to the drug are needed, but reports of single cases or few pregnancies exposed to PER could be important to provide preliminary information about its safety during gestation.

### Table 1

| Patient | PER dose | Concomitant ASMs | Time of fetal exposure to PER | Pregnancy Outcome | Birth parameters | Major Malformations |
|---------|----------|------------------|-----------------------------|-------------------|-----------------|---------------------|
| 1       | 8 mg/day | ZNS 500 mg/day   | 275 days                    | Full term         | Weight: 3500 g  | None                |
| 2       | 8 mg/day | CBZ 1800 mg/day  | 270 days                    | Full term         | Weight: 2660 g  | None                |
| 3       | 2 mg/day | None             | 185 days                    | Full term         | Weight: 2980 g  | None                |
| 4       | 6 mg/day | LEV 3000 mg/day  | 272 days                    | Full term         | Weight: 2690 g  | None                |

ZNS = zonisamide, CBZ = carbamazepine, LEV = levetiracetam, OXC = oxcarbazepine, PER = perampanel.
To date, 96 pregnancies have been reported in 90 women treated with PER (Table 2), which was taken as monotherapy in 26 cases. Forty-three (44%) pregnancies reached full term, with normal live births and no major malformations described; 28 pregnancies did not reach term (induced abortion, n = 18; spontaneous or incomplete spontaneous miscarriage, n = 8; premature delivery, n = 1; stillbirth [Fallot’s tetralogy], n = 1). Adverse events were reported in five newborns: low Apgar score in two cases, both on monotherapy; fatal neonatal aspiration in one case on concomitant carbamazepine and clobazam; cystic fibrosis and congenital deafness in 1 case with PER and two unspecified ASMs; poor sucking reflex and shallow breathing in one case with concomitant clonazepam [7].

Unlike previous works, which reported a low percentage (44%) of the full-term pregnancies, in our sample 3/3 pregnancies reached full term and PER showed overall a good safety profile, without side effects during pregnancies and without the occurrence of major congenital malformations or adverse events in their newborns.

Compared to previous reports, our cohort details perinatal metrics and newborn vital signs and parameters of all the pregnancies observed. The small sample size, brief follow-up and unavailability of PER plasma concentrations are the main limitations of our study.

6. Conclusion

The increasingly use of PER in women with epilepsy requires the need for more data on safety in special conditions like pregnancy. Single case reports or data involving small case series, though promising, are not enough evidence for the lack of teratogenesis and larger study populations are needed to reach more definitive conclusions.

Ethical publication statement

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Declaration of Competing Interest

ALN has received speaker’s or consultancy fees from Eisai, Mylan, Sanofi, Bial, GW, Arvelle Therapeutics, Angelini Pharma and UCB Pharma. GB has received speaker’s or consultancy fees from Eisai, Angelini Pharma and UCB Pharma. The remaining authors have no conflicts of interest to declare.
Acknowledgement

The study received no funding.

References

[1] Bobo WV, Davis RL, Toh S, et al. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001–2007: a medication exposure in pregnancy risk evaluation program study. Paediatr Perinat Epidemiol. 2012;26:578–88.

[2] Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53(Suppl 7):26–33.

[3] Rohracher A, Brigo F, Höfler J, et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother. 2016;17(10):1403–11.

[4] Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015;56(7):1006–19.

[5] European Medicines Agency. Fycompa®. Annex I: Summary of Product Characteristics, 2017. https://www.ema.europa.eu/en/documents/product-information/fycompa-eparproduct-information_en.pdf. Accessed 1 Oct 2020.

[6] Food and Drug Administration. FYCOMPA®. Prescribing information. September 2020. https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf. Accessed 1 Oct 2020.

[7] Vasquez B, Tomson T, Dobrinsky C, et al. Perampanel and pregnancy. Epilepsia 2021;62:698–708.